Antibacterial or antiviral composition

Abstract

To provide an antibacterial or antiviral composition.SOLUTION: An antibacterial or antiviral composition containing 2,2'-methylene bis(4,6-di-tert-butyl phenyl) sodium phosphate and a specific zinc salt exhibits excellent antibacterial property or antiviral property, and accordingly is usable as an antibacterial or antiviral processed article by blending the composition with a plastic material such as a resin compound, a film and a sheet, a coating agent such as a coating and a surface treatment agent, an adhesive, a fiber such as a woven fabric and a non-woven fabric, and paper.SELECTED DRAWING: None

Description

Technical Field

[0001] The present invention relates to an antibacterial or antiviral composition.

Background Art

[0002] Bacteria such as Escherichia coli and Staphylococcus aureus, or viruses such as influenza virus and norovirus, cause various diseases, and thus compositions having an effect against such bacteria and viruses are desired.

Summary of the Invention

Problems to be Solved by the Invention

[0003] An object of the present invention is to provide an antibacterial or antiviral composition that exhibits excellent performance against bacteria and viruses.

Means for Solving the Problems

[0004] As a result of intensive studies to solve such problems, the present inventors have arrived at the present invention. That is, the present invention is 〔1〕An antibacterial or antiviral composition containing sodium 2,2'-methylenebis(4,6-di-tert-butylphenyl) phosphate and a zinc salt represented by the following general formula (I). TIFF0007710715000001.tif4081(In the formula, R1 and R2 are the same and represent a linear or branched alkyl group having 5 to 28 carbon atoms or a linear or branched hydroxyalkyl group having 5 to 18 carbon atoms.) 〔2〕A processed product containing the above antibacterial or antiviral composition. is provided.

Effects of the Invention

[0005] According to the present invention, it is possible to provide an antibacterial or antiviral composition that exhibits excellent performance against bacteria or viruses.

Best Mode for Carrying Out the Invention

[0006] As the sodium 2,2'-methylenebis(4,6-di-tert-butylphenyl) phosphate used in the present invention, commercially available products can be used.

[0007] Examples of the zinc salt represented by the general formula (I) used in the present invention, wherein R1 and R2 are the same and represent a linear or branched alkyl group having 5 to 28 carbon atoms, include zinc octylate, zinc neodecanoate, zinc laurate, zinc stearate, zinc behenate, zinc montanate, etc. On the other hand, examples of the zinc salt in which one of R1 and R2 is the same and represents a linear or branched hydroxyalkyl group having 5 to 18 carbon atoms include zinc gluconate, zinc 1,2-hydroxystearate, zinc ricinoleate, etc.

[0008] Among these, when the zinc salt has a liquid property such as zinc octylate or zinc neodecanoate, it is preferably used by being supported on a carrier having an oil absorption amount in the range of 1.5 to 5 ml / g measured according to JIS K5101-13-1. Examples of the carrier include calcium silicate and silicon dioxide having the above oil absorption amount, such as Florite (registered trademark) R and RT (manufactured by Tomita Pharmaceutical Co., Ltd.), and Tokusil (registered trademark) NR (Oriental Silicas Corporation). When supporting on the carrier, usually, the weight of the zinc salt having the liquid property is supported so as to be 4 times or less the weight of the carrier.

[0009] The mixing ratio of sodium 2,2'-methylenebis(4,6-di-tert-butylphenyl) phosphate and the zinc salt is usually in the range of 1:9 to 9:1 by weight, preferably in the range of 2:8 to 8:2, and more preferably in the range of 3:7 to 7:3.

[0010] In the antibacterial or antiviral composition of the present invention, a light stabilizer, an ultraviolet absorber, etc. may be blended as necessary.

[0011] The antibacterial or antiviral composition of the present invention is usually incorporated into plastic agents such as resin compounds, films or sheets, coating agents such as paints and surface treatment agents, adhesives, fibers such as woven fabrics and non-woven fabrics, and papers, and is used as an antibacterial or antiviral processed product. Among these, when incorporated into a resin compound, it more preferably exhibits antibacterial or antiviral effects. Examples of resin compounds include polyethylene resin, polypropylene resin, polyvinyl chloride resin, polystyrene resin, acrylonitrile-butadiene-styrene resin, polyvinyl acetate resin, acrylic resin, polyurethane resin, polyamide resin, polycarbonate resin, polyester resin, polyethylene terephthalate resin, fluororesin, melamine resin, and the like.

[0012] In the above-mentioned antibacterial or antiviral processed product, the compounding amount of the antibacterial or antiviral composition of the present invention is 0.1 to 30% by weight, preferably 0.1 to 20% by weight, and more preferably 0.1 to 15% by weight, and is incorporated into the processed product.

[0013] Examples of bacteria targeted by the antibacterial composition of the present invention include Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, and the like. Examples of viruses targeted by the antiviral composition of the present invention include influenza virus, norovirus, coronavirus, rhinovirus, RS virus, adenovirus, enterovirus, and the like.

[0014] In the present invention, antibacterial property means suppressing the growth of bacteria. Also, antiviral property means suppressing the growth of viruses, killing viruses, and reducing the infectivity of viruses.

Examples

[0015] Hereinafter, the present invention will be specifically described by way of examples, but the present invention is not limited thereto.

Example 1

[0016] Zinc 2-ethylhexanoate (manufactured by Fujifilm Wako Pure Chemical Corporation, zinc octoate purity 99%) 63.2 parts by weight, sodium 2,2'-methylenebis-methylenebis(4,6-di-tert-butylphenyl) phosphate (manufactured by Tokyo Chemical Industry Co., Ltd.) 15.8 parts by weight, and Fluolite R 21.0 parts by weight were mixed to obtain the composition of the present invention. (Zinc 2-ethylhexanoate:sodium 2,2′-methylenebis(4,6-di-tert-butylphenyl) phosphate = 8:2)

Example 2

[0017] Zinc 2-ethylhexanoate (manufactured by Fujifilm Wako Pure Chemical Corporation, zinc octoate purity 99%) 56.8 parts by weight, sodium 2,2'-methylenebis-methylenebis(4,6-di-tert-butylphenyl) phosphate (manufactured by Tokyo Chemical Industry Co., Ltd.) 24.4 parts by weight, and Fluolite R 18.8 parts by weight were mixed to obtain the composition of the present invention. (Zinc 2-ethylhexanoate:sodium 2,2′-methylenebis(4,6-di-tert-butylphenyl) phosphate = 7:3)

Example 3

[0018] Zinc 2-ethylhexanoate (manufactured by Fujifilm Wako Pure Chemical Corporation, zinc octoate purity 99%) 42.9 parts by weight, sodium 2,2'-methylenebis-methylenebis(4,6-di-tert-butylphenyl) phosphate (manufactured by Tokyo Chemical Industry Co., Ltd.) 42.9 parts by weight, and Fluolite R 14.2 parts by weight were mixed to obtain the composition of the present invention. (Zinc 2-ethylhexanoate:sodium 2,2'-methylenebis-methylenebis(4,6-di-tert-butylphenyl) phosphate = 5:5)

Example 4

[0019] Zinc 2-ethylhexanoate (manufactured by Fujifilm Wako Pure Chemical Corporation, zinc octylate purity 99%) 27.3 parts by weight, sodium 2,2'-methylenebis-methylenebis(4,6-di-tert-butylphenyl) phosphate (manufactured by Tokyo Chemical Industry Co., Ltd.) 63.7 parts by weight, and Fluorite R 9.0 parts by weight were mixed to obtain the composition of the present invention. (Zinc 2-ethylhexanoate:sodium 2,2'-methylenebis-methylenebis(4,6-di-tert-butylphenyl) phosphate = 3:7)

Example 5

[0020] Zinc 2-ethylhexanoate (manufactured by Fujifilm Wako Pure Chemical Corporation, zinc octylate purity 99%) 18.8 parts by weight, sodium 2,2'-methylenebis-methylenebis(4,6-di-tert-butylphenyl) phosphate (manufactured by Tokyo Chemical Industry Co., Ltd.) 75.0 parts by weight, and Fluorite R 6.2 parts by weight were mixed to obtain the composition of the present invention. (Zinc 2-ethylhexanoate:sodium 2,2'-methylenebis-methylenebis(4,6-di-tert-butylphenyl) phosphate = 2:8) Comparative Example 1

[0021] Zinc 2-ethylhexanoate (manufactured by Fujifilm Wako Pure Chemical Corporation, zinc octylate purity 99%) 63.2 parts by weight and Fluorite R 21.0 parts by weight were mixed to obtain a comparative composition. Comparative Example 2

[0022] Sodium 2,2'-methylenebis-methylenebis(4,6-di-tert-butylphenyl) phosphate (manufactured by Tokyo Chemical Industry Co., Ltd.) was used as the comparative composition.

[0023] <Preparation of Test Pieces of Antiviral Resin Moldings> 100 parts of ZEST-1300 (polyvinyl chloride, manufactured by Shin-Etsu Chemical Co., Ltd.), 45 parts by weight of diisononyl phthalate, 6.2 parts by weight of epoxidized soybean oil, and 12.3 parts by weight of LBK-793K (manufactured by Sakai Chemical Industry Co., Ltd.) were mixed and kneaded at 170°C using a lab plastomill to obtain a PVC sol. With respect to 100 parts by weight of the PVC resin, the above compositions were kneaded so that the total amount of zinc 2-ethylhexanoate and sodium 2,2'-methylenebis (methylenebis (4,6-di-tert-butylphenyl)) phosphate was 1 part by weight to obtain resin compositions. The resin compositions were pressed for 3 minutes with a press molding machine heated to 180 ° C, and then cooled to room temperature to obtain polyvinyl chloride sheets with a thickness of 0.5 mm. Test pieces were obtained by cutting the sheets into 5 cm × 5 cm pieces.

[0024] (Antiviral activity test against influenza virus) According to ISO21702, influenza virus H3N2 strain (influenza A virus: A / Hong Kong / 8 / 68: TC adapted ATCC VR-1679) was cultured with MDCK cells (dog kidney-derived cells) to obtain a test influenza virus suspension with a virus infectious titer of 2×10 7 Plaque Forming Unit / ml (hereinafter referred to as PFU / ml). The test piece was placed in a plastic petri dish, and 0.4 ml of the above test influenza virus suspension was dropped onto the approximate center area of the test piece. Then, a 4 cm square polyethylene film was placed to cover the entire test virus suspension, and it was stored at 25 ° C and 95% humidity for 24 hours. Next, the test influenza virus suspension between the test piece and the polyethylene film was washed out with 10 ml of SCDLP medium (Nippon Pharmaceutical), and this washing solution was repeatedly diluted 10-fold using EMEM medium. The influenza virus infectious titer (logarithmic value of IV infectious titer) was measured by the plaque assay method using MDCK cells.

[0025] The measurement results of the influenza virus infectious titer are shown below.

[0026] [Table 1] TIFF0007710715000002.tif13150 [Example 6]

[0027] 50 parts by weight of zinc gluconate n-hydrate (manufactured by Fujifilm Wako Pure Chemical Corporation, zinc gluconate 88%) and 50 parts by weight of sodium 2,2'-methylenebis(4,6-di-tert-butylphenyl) phosphate (manufactured by Tokyo Chemical Industry Co., Ltd.) were mixed to obtain the composition of the present invention.

Example 7

[0028] 50 parts by weight of zinc laurate (manufactured by Fujifilm Wako Pure Chemical Corporation, zinc laurate content 13.7% as zinc) and 50 parts by weight of sodium 2,2'-methylenebis(4,6-di-tert-butylphenyl) phosphate (manufactured by Tokyo Chemical Industry Co., Ltd.) were mixed to obtain the composition of the present invention.

Example 8

[0029] 50 parts by weight of zinc stearate (manufactured by Fujifilm Wako Pure Chemical Corporation, zinc stearate content 13.3% as zinc oxide) and 50 parts by weight of sodium 2,2'-methylenebis(4,6-di-tert-butylphenyl) phosphate (manufactured by Tokyo Chemical Industry Co., Ltd.) were mixed to obtain the composition of the present invention. Comparative Example 3

[0030] Zinc gluconate n-hydrate (manufactured by Fujifilm Wako Pure Chemical Corporation, zinc gluconate 88%) was used as a comparative composition. Comparative Example 4

[0031] Zinc laurate (manufactured by Fujifilm Wako Pure Chemical Corporation, zinc laurate content 13.7% as zinc) was used as a comparative composition. Comparative Example 5

[0032] Zinc stearate (manufactured by Fujifilm Wako Pure Chemical Corporation, zinc stearate content 13.3% as zinc oxide) was used as a comparative composition.

[0033] <Preparation of Test Pieces of Antiviral Resin Moldings> 100 parts by weight of polyvinyl chloride resin prepared according to the formulation described in Paragraph 21 was kneaded with 1 part by weight of each of the compositions of Examples 4 to 6 and Comparative Examples 3 to 5 to obtain a resin composition. The resin composition was pressed at 180 °C for 3 minutes using a press molding machine and then cooled to room temperature to obtain a polyvinyl chloride sheet with a thickness of 0.5 mm. Test pieces were obtained by cutting the sheet into 5 cm × 5 cm pieces.

[0034] (Antiviral Activity Test Against Influenza Virus) The test was carried out according to the antiviral activity test against influenza virus described in Paragraph 24.

[0035] The measurement results of the influenza virus infection titer are shown below.

[0036] [Table 2] TIFF0007710715000003.tif13132

Claims

1. An antiviral composition containing sodium 2,2'-methylenebis(4,6-di-tert-butylphenyl) phosphate and a zinc salt represented by the following general formula (I). (In the formula, R1 and R2 are the same and represent a linear or branched alkyl group having 5 to 28 carbon atoms or a linear or branched hydroxyalkyl group having 5 to 18 carbon atoms.)

2. An antiviral processed product obtained by blending the antiviral composition according to Claim 1.

Images